ArticleWorld journal of microbiology & biotechnology2026
Restoration of β-lactam activity by nacubactam combinations against extensively drug-resistant K. pneumoniae harbouring diverse carbapenem resistance gene.
Article in World journal of microbiology & biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Carbapenem-resistant K. pneumoniae (CRKP) has emerged as a critical global health threat due to limited therapeutic options and high rates of multidrug resistance. Novel β-lactamase inhibitors such as Nacubactam may enhance the activity of conventional agents against carbapenemase-producing strains. Methods: This experimental study investigated 200 CRKP isolates identified using the VITEK 2.0 system and subjected to antimicrobial susceptibility testing. Carbapenemase production was assessed phenotypically by mCIM and eCIM assays, and molecular detection of resistance genes (NDM-1, OXA-48, KPC, VIM, IMP) was performed by multiplex PCR. Synergistic antimicrobial properties displayed when nacubactam is administered together with meropenem (MRP) and cefepime (CFM) was evaluated using checkerboard microdilution and time-kill spot assays. Results: Of 200 isolates, 150 (75%) demonstrated carbapenemase production. Among these, 65 (43.3%) were metallo-β-lactamase producers while 85 (56.6%) produced non-MBL carbapenemase (Serine type). Genotypic profiling revealed NDM-1 in 33.3% of isolates, OXA-48 in 31.8%, and KPC in 9.41%, with frequent co-harboring of multiple genes. None carried IMP or VIM gene. All isolates exhibited multidrug resistance, with 100% resistance to most β-lactams, aminoglycosides, fluoroquinolones, and carbapenems. Colistin remained universally active. Checkerboard assays demonstrated pronounced synergy of Nacubactam with meropenem against NDM-1, OXA-48, and KPC producers (FICI ≤ 0.285), while combinations with cefepime showed synergistic or additive activity (FICI 0.41–0.58). Time-kill assays confirmed bactericidal synergy, with ≥ 3 log₁₀ CFU reduction relative to single agents. Conclusion: This study highlights a high prevalence of NDM-1 and OXA-48 carbapenemase among CRKP isolates with extensive multidrug resistance. Nacubactam exhibited significant synergistic activity with meropenem, and moderate synergy with cefepime, across a range of genotypic variants. These findings suggest that Nacubactam–β-lactam combinations may represent a promising therapeutic strategy against CRKP infections, warranting further clinical evaluation.
Indexed as
Identifiers
41790301What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.